ChemoCentryx, Inc. - Revizia istoricului

127.0.0.1: The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

2024-11-24T18:12:49Z

The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

← Versiunea anterioară		Versiunea de la data 24 noiembrie 2024 21:12
Linia 2:		Linia 2:

	==Descriere companie==		==Descriere companie==
	ChemoCentryx, Inc. (www.chemocentryx.com) is a biopharmaceutical company that focuses on the development and commercialization of medications targeting inflammatory disorders, autoimmune diseases and cancer. Its drug candidates are designed to selectively block a specific chemoattractant receptor, leaving the rest of the immune system intact. The Company's lead drug candidate Avacopan is a potential first-in-class, an orally-administered molecule that targeted mode of action in the treatment of antineutrophil cytoplasmic antibodies (ANCA) vasculitis and other complement-driven autoimmune and inflammatory diseases. The Company is also developing Avacopan for the treatment of severe (Hurley stage III) hidradenitis suppurativa (HS). Its CCX559 is an orally administered inhibitor for programmed death protein [[one]]/programmed death-ligand 1 (PD-1/PD-L1), which are developing for the treatment of various cancers.		ChemoCentryx, Inc. (www.chemocentryx.com) is a biopharmaceutical company that focuses on the development and commercialization of medications targeting inflammatory disorders, autoimmune diseases and cancer. Its drug candidates are designed to selectively [[block]] a specific chemoattractant receptor, leaving the rest of the immune system intact. The Company's lead drug candidate Avacopan is a potential first-in-class, an orally-administered molecule that targeted mode of action in the treatment of antineutrophil cytoplasmic antibodies (ANCA) vasculitis and other complement-driven autoimmune and inflammatory diseases. The Company is also developing Avacopan for the treatment of severe (Hurley stage III) hidradenitis suppurativa (HS). Its CCX559 is an orally administered inhibitor for programmed death protein [[one]]/programmed death-ligand 1 (PD-1/PD-L1), which are developing for the treatment of various cancers.

	==Grafic actiuni companie==		==Grafic actiuni companie==

127.0.0.1: The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

2024-09-29T20:58:49Z

The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

← Versiunea anterioară		Versiunea de la data 29 septembrie 2024 23:58
Linia 2:		Linia 2:

	==Descriere companie==		==Descriere companie==
	ChemoCentryx, Inc. (www.chemocentryx.com) is a biopharmaceutical company that focuses on the development and commercialization of medications targeting inflammatory disorders, autoimmune diseases and cancer. Its drug candidates are designed to selectively block a specific chemoattractant receptor, leaving the rest of the immune system intact. The Company's lead drug candidate Avacopan is a potential first-in-class, an orally-administered molecule that targeted mode of action in the treatment of antineutrophil cytoplasmic antibodies (ANCA) vasculitis and other complement-driven autoimmune and inflammatory diseases. The Company is also developing Avacopan for the treatment of severe (Hurley stage III) hidradenitis suppurativa (HS). Its CCX559 is an orally administered inhibitor for programmed death protein one/programmed death-ligand 1 (PD-1/PD-L1), which are developing for the treatment of various cancers.		ChemoCentryx, Inc. (www.chemocentryx.com) is a biopharmaceutical company that focuses on the development and commercialization of medications targeting inflammatory disorders, autoimmune diseases and cancer. Its drug candidates are designed to selectively block a specific chemoattractant receptor, leaving the rest of the immune system intact. The Company's lead drug candidate Avacopan is a potential first-in-class, an orally-administered molecule that targeted mode of action in the treatment of antineutrophil cytoplasmic antibodies (ANCA) vasculitis and other complement-driven autoimmune and inflammatory diseases. The Company is also developing Avacopan for the treatment of severe (Hurley stage III) hidradenitis suppurativa (HS). Its CCX559 is an orally administered inhibitor for programmed death protein [[one]]/programmed death-ligand 1 (PD-1/PD-L1), which are developing for the treatment of various cancers.

	==Grafic actiuni companie==		==Grafic actiuni companie==

Admin: Pagină nouă: Pagina dedicata companiei ChemoCentryx, Inc. listata cu simbolul US.CCXI ==Descriere companie== ChemoCentryx, Inc. (www.chemocentryx.com) is a biopharmaceutical company that focuses on the development and commercialization of medications targeting inflammatory disorders, autoimmune diseases and cancer. Its drug candidates are designed to selectively block a specific chemoattractant receptor, leaving the rest of the immune system intact. The Company's lead drug candidate Avac...

2024-09-18T13:45:52Z

Pagină nouă: Pagina dedicata companiei ChemoCentryx, Inc. listata cu simbolul US.CCXI ==Descriere companie== ChemoCentryx, Inc. (www.chemocentryx.com) is a biopharmaceutical company that focuses on the development and commercialization of medications targeting inflammatory disorders, autoimmune diseases and cancer. Its drug candidates are designed to selectively block a specific chemoattractant receptor, leaving the rest of the immune system intact. The Company's lead drug candidate Avac...

Pagină nouă

Pagina dedicata companiei ChemoCentryx, Inc. listata cu simbolul US.CCXI

==Descriere companie==
ChemoCentryx, Inc. (www.chemocentryx.com) is a biopharmaceutical company that focuses on the development and commercialization of medications targeting inflammatory disorders, autoimmune diseases and cancer. Its drug candidates are designed to selectively block a specific chemoattractant receptor, leaving the rest of the immune system intact. The Company's lead drug candidate Avacopan is a potential first-in-class, an orally-administered molecule that targeted mode of action in the treatment of antineutrophil cytoplasmic antibodies (ANCA) vasculitis and other complement-driven autoimmune and inflammatory diseases. The Company is also developing Avacopan for the treatment of severe (Hurley stage III) hidradenitis suppurativa (HS). Its CCX559 is an orally administered inhibitor for programmed death protein one/programmed death-ligand 1 (PD-1/PD-L1), which are developing for the treatment of various cancers.

==Grafic actiuni companie==
<iframe key="tradeville" path="graficSimbol/US.CCXI" />

==Ultimele stiri despre ChemoCentryx, Inc. (US.CCXI)==
<dynamicpagelist>
category=US.CCXI
count=10
order=descending
addfirstcategorydate=false
</dynamicpagelist>

[[Categorie:US.CCXI]][[Categorie:Stiri despre companii]]